A study by a scientific team from the University of Vienna and the MedUni Vienna, recently published in Cellular & Molecular Immunology, shows that the enzyme phosphoglycerate dehydrogenase (PHGDH) acts as a metabolic checkpoint ...
Feb 27, 2024
0
42
The colon is often thought of as one organ, but the right and left parts of the colon have different molecular features in cancers. New research in mice from investigators at the Johns Hopkins Kimmel Cancer Center demonstrates ...
Feb 27, 2024
0
32
Head and neck squamous cell carcinoma (HNSCC) is a type of cancer that affects the mucous membranes of the mouth, nose, and throat. HNSCC is typically associated with tobacco exposure, alcohol abuse, and viral infections. ...
Feb 27, 2024
0
0
Researchers at the Technion's Ruth and Bruce Rappaport Faculty of Medicine and the Rappaport Family Institute for Research in the Medical Sciences have discovered a subset of blood cells that predict the success of immunotherapy ...
Feb 26, 2024
0
52
In an early-phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumor activity in individuals with various types of advanced cancer. The findings ...
Feb 26, 2024
0
34
In a new editorial paper published in Oncoscience titled, "A very long and winding road: developing novel therapeutics for metastatic tumors," researcher Paul Dent from the Department of Biochemistry and Molecular Biology ...
Feb 26, 2024
0
0
Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, is one of the first centers nationwide to offer a newly approved cell-based immunotherapy that targets melanoma.
Feb 24, 2024
0
1
Successful immunotherapy for cancer involves activating a person's own T cells to identify telltale proteins called antigens on the surface of a tumor and attack it. But some tumors have a trick: They hide themselves from ...
Feb 22, 2024
0
32
An analysis of blood and tumor samples from patients in a clinical trial comparing two therapies for advanced renal cell carcinoma shows that different immunomodulatory mechanisms are at work depending on the type of treatment ...
Feb 22, 2024
0
0
CureLab Oncology, a clinical-stage, pre-IPO biotech company, announced that its novel biological agent, Elenagen, has been shown to significantly enhance standard chemotherapy and provides clinical benefits for the patients ...
Feb 22, 2024
0
0
